Ras

HDAC Inhibitor:
Vorinostat (SAHA)

HDAC (Histone deacetylase)
## Ras Inhibitors & Modulators

### 6H05  
**K-Ras inhibitor**

**Bioactivity:** 6H05 is a selective, and allosteric inhibitor of oncogenic mutant K-Ras(G12C).

**Purity:** >98%

**Clinical Data:**
- **Size:** 5 mg, 10 mg

### 6H05 (trifluoroacetate)  
**K-Ras inhibitor**

**Bioactivity:** 6H05 trifluoroacetate is a selective, and allosteric inhibitor of oncogenic mutant K-Ras(G12C).

**Purity:** >98%

**Clinical Data:**
- **Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg

### ARS-853  
**(ARS853; ARS 853)**

**Bioactivity:** ARS-853 is a selective, covalent \(\text{KRAS}^{G12C}\) inhibitor with \(IC_{50}\) of 2.5 \(\mu\)M.

**Purity:** 98.39%

**Clinical Data:**
- **Size:** 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg

### BQU57  
**(BQU-57)**

**Bioactivity:** BQU57 shows selective inhibition for Ral relative to Ras or Rho and inhibit xenograft tumor growth similar to depletion of Ral by siRNA. The IC50 for BQU57 of 2.0 \(\mu\)M in H2122 and 1.3 \(\mu\)M in H358.

**Purity:** 98.33%

**Clinical Data:**
- **Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

### CASIN  

**Bioactivity:** CASIN is a selective GTPase Cdc42 inhibitor with IC50 of 2 \(\mu\)M.

**Purity:** 98.03%

**Clinical Data:**
- **Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

### CCG-1423  

**Bioactivity:** CCG-1423 is a novel inhibitor of RhoA/C-mediated gene transcription that is capable of inhibiting invasion of PC-3 prostate cancer cells in a Matrigel model of metastasis.

**Purity:** 99.94%

**Clinical Data:**
- **Size:** 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg

### EHop-016  

**Bioactivity:** EHop-016 is a novel potent and selective inhibitor of Rac GTPase; inhibits Rac1 activity in MDA-MB-435 cells with an IC50 of 1.1 \(\mu\)M.

**Purity:** 98.91%

**Clinical Data:**
- **Size:** 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg

### EHT 1864  
**(EHT1864; EHT-1864)**

**Bioactivity:** EHT 1864 is a small molecule inhibitor of Rac1 signaling; modulate \(\gamma\)-Secretase-mediated APP processing.

**Purity:** 99.61%

**Clinical Data:**
- **Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg

### K-Ras G12C-IN-1  

**Bioactivity:** K-Ras G12C-IN-1 is a novel and irreversible inhibitor of mutant K-ras G12C.

**Purity:** 98.19%

**Clinical Data:**
- **Size:** 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

### K-Ras G12C-IN-2  

**Bioactivity:** K-Ras G12C-IN-2 is a novel and irreversible inhibitor of G12C mutant K-Ras protein.

**Purity:** >98.0%

**Clinical Data:**
- **Size:** 1 mg, 5 mg, 10 mg, 50 mg, 100 mg
<table>
<thead>
<tr>
<th><strong>K-Ras G12C-IN-3</strong></th>
<th><strong>K-Ras (G12C) inhibitor 12</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bioactivity:</strong> K-Ras G12C-IN-3 is a novel and irreversible inhibitor of mutant K-ras G12C.</td>
<td><strong>Bioactivity:</strong> K-Ras (G12C) inhibitor 12 is a K-Ras (G12C) inhibitor, the half-maximum effective concentration (EC50) for K-Ras (G12C) inhibitor 12 in H1792 cells is 0.32 μM.</td>
</tr>
<tr>
<td><strong>Purity:</strong> 99.92%</td>
<td><strong>Purity:</strong> &gt;98.0%</td>
</tr>
<tr>
<td><strong>Clinical Data:</strong> Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg</td>
<td><strong>Clinical Data:</strong> Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>K-Ras-IN-1</strong></th>
<th><strong>Kobe0065</strong> (Kobe 0065; Kobe-0065)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bioactivity:</strong> K-Ras-IN-1 is a K-Ras inhibitor, by binding to K-Ras in a hydrophobic pocket that is occupied by Tyr-71 in the apo-Ras crystal structure. (the detailed information refer to the reference)</td>
<td><strong>Bioactivity:</strong> Kobe0065 is a novel and effective inhibitor of Ras-Raf interaction, competitively inhibiting the binding of H-Ras·GTP to c-Raf-1 RBD with a K_i value of 46±13 μM.</td>
</tr>
<tr>
<td><strong>Purity:</strong> 98.06%</td>
<td><strong>Purity:</strong> 99.26%</td>
</tr>
<tr>
<td><strong>Clinical Data:</strong> Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg</td>
<td><strong>Clinical Data:</strong> Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 200 mg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>kobe2602</strong> (kobe 2602; kobe-2602)</th>
<th><strong>ML-098</strong> (CID-7345532; CID 7345532; CID7345532; ML 098; ML098)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bioactivity:</strong> Kobe2602 is a novel and effective small-molecule compound inhibiting Ras-Raf interaction by SBDD; exhibits potent activity to competitively inhibit the binding of H-Ras·GTP to c-Raf-1 RBD with a K_i value of 149 ± 55 μM.</td>
<td><strong>Bioactivity:</strong> ML-098 (CID-7345532) is an activator of the GTP-binding protein Rab7 with an EC_{50} of 77.6 nM.</td>
</tr>
<tr>
<td><strong>Purity:</strong> 96.97%</td>
<td><strong>Purity:</strong> &gt;98%</td>
</tr>
<tr>
<td><strong>Clinical Data:</strong> Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 200 mg</td>
<td><strong>Clinical Data:</strong> Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>ML141</strong> (ML-141; CID-2950007)</th>
<th><strong>NSC 23766</strong> (NSC-23766; NSC23766)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bioactivity:</strong> ML141 (CID-2950007) is a potent, selective and reversible non-competitive inhibitor of Cdc42 GTPase (IC50=200 nM) with low micromolar potency and selectivity against other members of the Rho family of GTPases (Rac1, Rab2, Rab7).</td>
<td><strong>Bioactivity:</strong> NSC 23766 is a specific inhibitor of the binding and activation of RAC GTPase with IC50 of ~50 μM; does not inhibit the closely related targets, Cdc42 or RhoA.</td>
</tr>
<tr>
<td><strong>Purity:</strong> 99.51%</td>
<td><strong>Purity:</strong> &gt;98%</td>
</tr>
<tr>
<td><strong>Clinical Data:</strong> Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg</td>
<td><strong>Clinical Data:</strong> Size: 5 mg, 10 mg, 50 mg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>NSC 23766 (trihydrochloride)</strong> (NSC-23766 trihydrochloride; NSC23766 trihydrochloride)</th>
<th><strong>Onocrasin-1</strong> (Onocrasin 1; Oncrasin1)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bioactivity:</strong> NSC 23766·HCl is a specific inhibitor of the binding and activation of RAC GTPase with IC50 of ~50 μM; does not inhibit the closely related targets, Cdc42 or RhoA.</td>
<td><strong>Bioactivity:</strong> Oncrasin-1 is a potent and effective anticancer inhibitor that kills various human lung cancer cells with K-Ras mutations at low or submicromolar concentrations; also led to abnormal aggregation of PKCι in nucleus of sensitive cells but not in resistant cells.</td>
</tr>
<tr>
<td><strong>Purity:</strong> &gt;98.0%</td>
<td><strong>Purity:</strong> 98.74%</td>
</tr>
<tr>
<td><strong>Clinical Data:</strong> Size: 10mM x 1mL in Water, 5 mg, 10 mg, 50 mg</td>
<td><strong>Clinical Data:</strong> Size: 10mM x 1mL in DMSO, 10 mg, 50 mg</td>
</tr>
</tbody>
</table>
| **RBC8**  
| (RBC-8)  
| **Cat. No.: HY-12873**  
| **Bioactivity:** RBC8 is a novel small molecule inhibitor of Ral GTPase; has IC50 of 3.5 μM in H2122 cell and 3.4 μM in H358 cell.  
| **Purity:** >98.0%  
| **Clinical Data:**  
| **Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg  
|  
| **Rhosin**  
| **Cat. No.: HY-12646A**  
| **Bioactivity:** Rhosin is a specific Rho inhibitor; binds to WT RhoA with an affinity ~0.4 μM Kd; does not interfere with the binding of Cdc42 or Rac1.  
| **Purity:** >98%  
| **Clinical Data:**  
| **Size:** 5 mg, 10 mg  
|  
| **Rhosin (hydrochloride)**  
| **Cat. No.: HY-12646**  
| **Bioactivity:** Rhosin Hcl is a specific Rho inhibitor; binds to WT RhoA with an affinity ~0.4 μM Kd; does not interfere with the binding of Cdc42 or Rac1.  
| **Purity:** 99.98%  
| **Clinical Data:**  
| **Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg  
|  
| **Salirasib** (S-Farnesylthiosalicylic acid; Farnesyland Thiosalicylic Acid; FTS)  
| **Cat. No.: HY-14754**  
| **Bioactivity:** Salirasib is a potent and competitive prenylated protein methyltransferase (PPMTase) inhibitor with Ki of 2.6 μM, which inhibits Ras methylation.  
| **Purity:** 98.47%  
| **Clinical Data:**  
| **Phase 1, Phase 2**  
| **Size:** 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg  
|  
| **Y16**  
| (Y-16)  
| **Cat. No.: HY-12649**  
| **Bioactivity:** Y16 is an inhibitor of G-protein–coupled Rho GEFs; works synergistically with Rhosin/G04 in inhibiting LARG-RhoA interaction, RhoA activation, and RhoA-mediated signaling functions.  
| **Purity:** 98.93%  
| **Clinical Data:**  
| **Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg  
|  
| **ZCL278**  
| (ZCL 278; ZCL-278)  
| **Cat. No.: HY-13963**  
| **Bioactivity:** ZCL278 is a selective Cdc42 modulator that directly binds to Cdc42 and inhibits its functions with Ki of 11.4 μM for Cdc42-ZCL278 affinity in surface plasmon resonance (SPR) experiment.  
| **Purity:** 95.11%  
| **Clinical Data:**  
| **Size:** 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg  

Tel: 609-228-6898  
Fax: 609-228-5909  
Email: sales@medchemexpress.com